CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) therapy(Childrens Hospital of Philadelphia)

N/A

Report date: 2025/02/28 20:00:34

Base Information

Drug NameCD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) therapy(Childrens Hospital of Philadelphia)

Drug Alias NameCART19

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLupus Erythematosus, SystemicLupus NephritisLupus Vulgaris

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesChildrens Hospital of Philadelphia

China Registration ClassN/A

Develop Information

Active CompaniesChildrens Hospital of Philadelphia

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, SystemicLupus NephritisLupus Vulgaris

Inactive IndicationsN/A

Other Information

ATC CodeN/A